Skip to main content
SpringerLink
Log in

Role of Antifungal Therapy in Complicated Intra-abdominal Infections

  • Intra-Abdominal Infections, Hepatitis and Gastroenteritis (T Steiner, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this narrative review, we discuss key questions about the antifungal treatment of complicated intrabdominal infections (cIAI).

Recent Findings

Although less common than bacteria, Candida spp. are not an infrequent cause of cIAI. Considering that invasive abdominal candidiasis (IAC) may be accompanied by septic shock in up to 40% of cases, empirical antifungal treatment should be considered while waiting for rapid tests and cultures results, and it should be guided by the presence of risk factors for invasive candidiasis in patients with consistent signs and symptoms. Early antifungal therapy before availability of culture results can be partly based on the results of rapid diagnostic tests such as antigen/antibody assays or other rapid methods, although it should be noted that most data pertaining to the use of rapid tests refer to candidemia or invasive candidiasis in general, and not specifically to IAC, thus clinical judgment still remains crucial. Although cultures are hampered by a slow turnaround time, they remain of paramount importance, by allowing identification at species level and antifungal susceptibility testing.

Summary

Together with source control, adequate antifungal therapy is an essential component of the correct approach to IAC. Future research should focus on enriching our knowledge on the diagnostic performance of rapid tests in cIAI, and on providing a standardized definition for IAC. Advancements in these fields are crucial for improving the correct use of antifungals at the bedside of cIAI patients and also for reducing unnecessary antifungal use in line with antifungal stewardship principles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Bassetti M, Eckmann C, Giacobbe DR, Sartelli M, Montravers P. Post-operative abdominal infections: epidemiology, operational definitions, and outcomes. Intensive Care Med. 2019;46(2):163–72. https://doi.org/10.1007/s00134-019-05841-5A recent review regarding current major clinical and research questions in the field of cIAI.

    Article  PubMed  Google Scholar 

  2. Bassetti M, Righi E, Ansaldi F, Merelli M, Scarparo C, Antonelli M, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015;41:1601–10.

    PubMed  Google Scholar 

  3. De Waele J, Lipman J, Sakr Y, Marshall JC, Vanhems P, Barrera Groba C, et al. Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. BMC Infect Dis. 2014;14:420.

    PubMed  PubMed Central  Google Scholar 

  4. Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the ciaow study. World J Emerg Surg. 2014;9:37.

    PubMed  PubMed Central  Google Scholar 

  5. Sartelli M, Weber DG, Ruppe E, Bassetti M, Wright BJ, Ansaloni L, et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (agora). World J Emerg Surg. 2016;11:33.

    PubMed  PubMed Central  Google Scholar 

  6. • Montravers P, Blot S, Dimopoulos G, Eckmann C, Eggimann P, Guirao X, et al. Therapeutic management of peritonitis: a comprehensive guide for intensivists. Intensive Care Med. 2016;42:1234–47 Discussion of the approach to peritonitis from the intensivist’s perspective.

    CAS  PubMed  Google Scholar 

  7. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med. 2013;39:2092–106.

    PubMed  Google Scholar 

  8. Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse JP, et al. Predictive factors of mortality due to polymicrobial peritonitis with candida isolation in peritoneal fluid in critically ill patients. Arch Surg. 2002;137:1341–6 discussion 47.

    PubMed  Google Scholar 

  9. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34:646–52.

    PubMed  Google Scholar 

  10. Sandven P, Qvist H, Skovlund E, Giercksky KE, N. Group, G. the Norwegian Yeast Study. Significance of candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med. 2002;30:541–7.

    PubMed  Google Scholar 

  11. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.

    PubMed  Google Scholar 

  12. Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, et al. Incidence and outcome of invasive candidiasis in intensive care units (icus) in europe: results of the eucandicu project. Crit Care. 2019;23:219.

    PubMed  PubMed Central  Google Scholar 

  13. •• Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, et al. Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the fungal infections definitions in icu patients (fundicu) project. Mycoses. 2019;62:310–9 Protocol of the FUNDICU project aimed at developing standard definitions for invasive fungal diseases in critically ill patients.

    PubMed  Google Scholar 

  14. de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PH. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection. 2009;37:522–7.

    PubMed  Google Scholar 

  15. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med. 2003;31:752–7.

    PubMed  Google Scholar 

  16. Lee SC, Fung CP, Chen HY, Li CT, Jwo SC, Hung YB, et al. Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin b. Diagn Microbiol Infect Dis. 2002;44:23–7.

    PubMed  Google Scholar 

  17. Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system (“candida score”) for early antifungal treatment in nonneutropenic critically ill patients with candida colonization. Crit Care Med. 2006;34:730–7.

    PubMed  Google Scholar 

  18. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, et al. Usefulness of the “candida score” for discriminating between candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624–33.

    PubMed  Google Scholar 

  19. Ostrosky-Zeichner L. New approaches to the risk of candida in the intensive care unit. Curr Opin Infect Dis. 2003;16:533–7.

    PubMed  Google Scholar 

  20. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med. 2014;40:1429–48.

    PubMed  PubMed Central  Google Scholar 

  22. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, et al. Esicm/escmid task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45:789–805. https://doi.org/10.1007/s00134-019-05599-w.

    Article  PubMed  Google Scholar 

  23. Perlin DS. Echinocandin resistance in candida. Clin Infect Dis. 2015;61(Suppl 6):S612–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Grau S, Luque S, Campillo N, Samso E, Rodriguez U, Garcia-Bernedo CA, et al. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother. 2015;70:2854–61.

    CAS  PubMed  Google Scholar 

  25. Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, et al. Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother. 2015;59:4403–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Colbers A, et al. Pharmacokinetics of caspofungin in icu patients. J Antimicrob Chemother. 2014;69:3294–9.

    CAS  PubMed  Google Scholar 

  27. Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (dali) patients study. Crit Care. 2015;19:33.

    PubMed  PubMed Central  Google Scholar 

  28. Dupont H, Massias L, Jung B, Ammenouche N, Montravers P. Pharmacokinetic study of anidulafungin in icu patients with intra-abdominal candidiasis. J Antimicrob Chemother. 2017;72:1429–32.

    CAS  PubMed  Google Scholar 

  29. Dagens A, Mughal N, Sisson A, Moore LSP. Experience of using beta-d-glucan assays in the intensive care unit. Crit Care. 2018;22:125.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Donato L, Gonzalez T, Canales M, Legarraga P, Garcia P, Rabagliati R. the 1,3-beta-d-glucan in critical adult patients as diagnostic tool for invasive Candida spp. Infection, performance evaluation. Rev Chil Infectol. 2017;34:340–6 Evaluación del rendimiento de 1,3-β-d-glucano como apoyo diagnóstico de infecciones invasoras por Candida spp. en pacientes críticos adultos.

    Google Scholar 

  31. Mikulska M, Giacobbe DR, Furfaro E, Mesini A, Marchese A, Del Bono V, et al. Lower sensitivity of serum (1,3)-beta-d-glucan for the diagnosis of candidaemia due to Candida parapsilosisClin Microbiol Infect. 2016;22:646.e5–8.

    PubMed  Google Scholar 

  32. Nucci M, Nouer SA, Esteves P, Guimaraes T, Breda G, de Miranda BG, et al. Discontinuation of empirical antifungal therapy in icu patients using 1,3-beta-d-glucan. J Antimicrob Chemother. 2016;71:2628–33.

    CAS  PubMed  Google Scholar 

  33. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1-->3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654–9.

    CAS  PubMed  Google Scholar 

  34. Posteraro B, Tumbarello M, De Pascale G, Liberto E, Vallecoccia MS, De Carolis E, et al. (1,3)-beta-d-glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: An observational study. J Antimicrob Chemother. 2016;71:2262–9.

    CAS  PubMed  Google Scholar 

  35. Talento AF, Dunne K, Joyce EA, Palmer M, Johnson E, White PL, et al. A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit. J Crit Care. 2017;40:119–27.

    PubMed  Google Scholar 

  36. Tissot F, Lamoth F, Hauser PM, Orasch C, Fluckiger U, Siegemund M, et al. Beta-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med. 2013;188:1100–9.

    PubMed  Google Scholar 

  37. Duettmann W, Koidl C, Krause R, Lackner G, Woelfler A, Hoenigl M. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses. 2016;59:374–8.

    CAS  PubMed  Google Scholar 

  38. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C, Third European G. Conference on infections in leukemia. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the third european conference on infections in leukemia. Crit Care. 2010;14:R222.

    PubMed  PubMed Central  Google Scholar 

  39. Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis. 2005;51:95–101.

    CAS  PubMed  Google Scholar 

  40. Sendid B, Poirot JL, Tabouret M, Bonnin A, Caillot D, Camus D, et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic candida species. J Med Microbiol. 2002;51:433–42.

    CAS  PubMed  Google Scholar 

  41. Verduyn Lunel FM, Donnelly JP, van der Lee HA, Blijlevens NM, Verweij PE. Circulating candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect. 2009;15:380–6.

    CAS  PubMed  Google Scholar 

  42. Leon C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I, et al. Contribution of candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in icu patients with severe abdominal conditions. Crit Care. 2016;20:149.

    PubMed  PubMed Central  Google Scholar 

  43. Clancy CJ, Nguyen MH. Non-culture diagnostics for invasive candidiasis: Promise and unintended consequences. J Fungi (Basel). 2018;4:7.

    Google Scholar 

  44. Martinez-Jimenez MC, Munoz P, Guinea J, Valerio M, Alonso R, Escribano P, et al. Potential role of candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. Med Mycol. 2014;52:270–5.

    CAS  PubMed  Google Scholar 

  45. Martinez-Jimenez MC, Munoz P, Valerio M, Vena A, Guinea J, Bouza E. Combination of candida biomarkers in patients receiving empirical antifungal therapy in a spanish tertiary hospital: a potential role in reducing the duration of treatment. J Antimicrob Chemother. 2016;71:2679.

    CAS  PubMed  Google Scholar 

  46. Parra-Sanchez M, Zakariya-Yousef Breval I, Castro Mendez C, Garcia-Rey S, Loza Vazquez A, Ubeda Iglesias A, et al. Candida albicans germ-tube antibody: evaluation of a new automatic assay for diagnosing invasive candidiasis in icu patients. Mycopathologia. 2017;182:645–52.

    CAS  PubMed  Google Scholar 

  47. Wei S, Wu T, Wu Y, Ming D, Zhu X. Diagnostic accuracy of candida albicans germ tube antibody for invasive candidiasis: systematic review and meta-analysis. Diagn Microbiol Infect Dis. 2019;93:339–45.

    CAS  PubMed  Google Scholar 

  48. Giacobbe DR, Mikulska M, Tumbarello M, Furfaro E, Spadaro M, Losito AR, et al. Combined use of serum (1,3)-beta-d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Crit Care. 2017;21:176.

    PubMed  PubMed Central  Google Scholar 

  49. Martinez-Jimenez MC, Munoz P, Valerio M, Alonso R, Martos C, Guinea J, et al. Candida biomarkers in patients with candidaemia and bacteraemia. J Antimicrob Chemother. 2015;70:2354–61.

    CAS  PubMed  Google Scholar 

  50. Avni T, Leibovici L, Paul M. Pcr diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665–70.

    PubMed  PubMed Central  Google Scholar 

  51. Chang SS, Hsieh WH, Liu TS, Lee SH, Wang CH, Chou HC, et al. Multiplex pcr system for rapid detection of pathogens in patients with presumed sepsis—a systemic review and meta-analysis. PLoS One. 2013;8:e62323.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Desmet S, Maertens J, Bueselinck K, Lagrou K. Broad-range pcr coupled with electrospray ionization time of flight mass spectrometry for detection of bacteremia and fungemia in patients with neutropenic fever. J Clin Microbiol. 2016;54:2513–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. White PL, Hibbitts SJ, Perry MD, Green J, Stirling E, Woodford L, et al. Evaluation of a commercially developed semiautomated pcr-surface-enhanced raman scattering assay for diagnosis of invasive fungal disease. J Clin Microbiol. 2014;52:3536–43.

    PubMed  PubMed Central  Google Scholar 

  54. Bassetti M, Righi E, Montravers P, Cornely OA. What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother. 2018;73:i14–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Arendrup MC, Andersen JS, Holten MK, Krarup KB, Reiter N, Schierbeck J, et al. Diagnostic performance of T2Candida among ICU patients with risk factors for invasive candidiasis. Open Forum Infect Dis. 2019;6:ofz136.

    PubMed  PubMed Central  Google Scholar 

  56. Bouza E, Vena A, Munoz P, T. M. s. group. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study–authors' response. J Antimicrob Chemother. 2019;74:533–4.

    CAS  PubMed  Google Scholar 

  57. Giannella M, Paolucci M, Roncarati G, Vandi G, Pascale R, Trapani F, et al. Potential role of t2candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-Centre study. J Antimicrob Chemother. 2018;73:2856–9.

    CAS  PubMed  Google Scholar 

  58. Munoz P, Vena A, Machado M, Gioia F, Martinez-Jimenez MC, Gomez E, et al. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. J Antimicrob Chemother. 2018;73:iv6–iv12.

    CAS  PubMed  Google Scholar 

  59. Clancy CJ, Nguyen MH. T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. J Antimicrob Chemother. 2018;73:iv2–5.

    CAS  PubMed  Google Scholar 

  60. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60:892–9.

    CAS  PubMed  Google Scholar 

  61. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. Escmid* guideline for the diagnosis and management of candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18(Suppl 7):9–18.

    CAS  PubMed  Google Scholar 

  62. Bailly S, Leroy O, Montravers P, Constantin JM, Dupont H, Guillemot D, et al. Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Med. 2015;41:1931–40.

    CAS  PubMed  Google Scholar 

  63. Vazquez J, Reboli AC, Pappas PG, Patterson TF, Reinhardt J, Chin-Hong P, et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis. 2014;14:97.

    PubMed  PubMed Central  Google Scholar 

  64. Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg. 2000;24:32–7.

    CAS  PubMed  Google Scholar 

  65. Seiler CA, Brugger L, Forssmann U, Baer HU, Buchler MW. Conservative surgical treatment of diffuse peritonitis. Surgery. 2000;127:178–84.

    CAS  PubMed  Google Scholar 

  66. Azuhata T, Kinoshita K, Kawano D, Komatsu T, Sakurai A, Chiba Y, et al. Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. Crit Care. 2014;18:R87.

    PubMed  PubMed Central  Google Scholar 

  67. Bloos F, Ruddel H, Thomas-Ruddel D, Schwarzkopf D, Pausch C, Harbarth S, et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. Intensive Care Med. 2017;43:1602–12.

    PubMed  Google Scholar 

  68. Martin-Loeches I, Timsit JF, Leone M, de Waele J, Sartelli M, Kerrigan S, et al. Clinical controversies in abdominal sepsis. Insights for critical care settings. J Crit Care. 2019;53:53–8.

    PubMed  Google Scholar 

  69. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77.

    PubMed  Google Scholar 

  70. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066–72.

    CAS  PubMed  Google Scholar 

  71. Khoury W, Szold O, Soffer D, Kariv Y, Wasserlauf R, Klausner JM, et al. Prophylactic fluconazole does not improve outcome in patients with purulent and fecal peritonitis due to lower gastrointestinal perforation. Am Surg. 2010;76:197–202.

    PubMed  Google Scholar 

  72. Senn L, Eggimann P, Ksontini R, Pascual A, Demartines N, Bille J, et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med. 2009;35:903–8.

    PubMed  Google Scholar 

  73. •• Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Raineri SM, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev. 2016;2016(1):CD004920. https://doi.org/10.1002/14651858.CD004920Comprehensive systematic review about the role of antifungal prophylaxis in non-neutropenic critically ill patients.

    Article  PubMed Central  Google Scholar 

  74. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med. 2005;31:1479–87.

    PubMed  Google Scholar 

  75. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006;57:628–38.

    CAS  PubMed  Google Scholar 

  76. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005;33:1928–35 quiz 36.

    CAS  PubMed  Google Scholar 

  77. Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med. 2006;34:1216–24.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Unit, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy

    Matteo Bassetti, Antonio Vena, Rachele Pincino, Federica Briano & Daniele Roberto Giacobbe

  2. Department of Health Sciences, University of Genoa, Genoa, Italy

    Matteo Bassetti, Rachele Pincino & Federica Briano

Authors
  1. Matteo Bassetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Vena
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachele Pincino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Federica Briano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniele Roberto Giacobbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Bassetti.

Ethics declarations

Conflict of Interest

Outside the submitted work, MB has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, Bayer, Basilea, BioMérieux, Cidara, Gilead, Menarini, MSD, Nabriva, Paratek, Pfizer, Roche, Melinta, Shionogi, Tetraphase, VenatoRx, and Vifor and has received study grants from Angelini, Basilea, Astellas, Shionogi, Cidara, Melinta, Gilead, Pfizer, and MSD. Outside the submitted work, DRG reports honoraria from Stepstone Pharma GmbH and an unconditional grant from MSD Italia. The other authors have no conflicts of interest to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by either of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Intra-Abdominal Infections, Hepatitis and Gastroenteritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bassetti, M., Vena, A., Pincino, R. et al. Role of Antifungal Therapy in Complicated Intra-abdominal Infections. Curr Infect Dis Rep 22, 21 (2020). https://doi.org/10.1007/s11908-020-00731-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-020-00731-0

Keywords

Search

Navigation